Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Traws Pharma ( (TRAW) ).
On September 9, 2025, Traws Pharma, Inc. completed the purchase of certain assets from Virom, Inc. for $2,350,000, including intellectual property and assets related to a pyrrolidine antiviral compound. This acquisition, approved by Traws Pharma’s Audit Committee and Board of Directors, aims to enhance the company’s program pipeline and product offerings, potentially strengthening its market position in antiviral pharmaceuticals.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on antiviral compounds and related pharmaceutical products.
Average Trading Volume: 111,440
Technical Sentiment Signal: Sell
Current Market Cap: $12.79M
For an in-depth examination of TRAW stock, go to TipRanks’ Overview page.